NASDAQ$NKGN

Nkgen Biotech Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Headline financials

Total Revenue

$0.00

No prior period
EPS (adj)

-$0.59

Previous: $0.05-1280.0%
Capital Expenditures

$0.00

No prior period
Free Cash Flow

-$552K

No prior period
Net Income

-$1.83M

Previous: $956K-291.5%
Operating Income

-$2.68M

Previous: -$969K-176.2%
Gross Profit

$0.00

No prior period
Cash & Equivalents

$41.5K

Previous: $1.26M-96.7%
Total Assets

$63.6M

Previous: $174M-63.4%
Stock-Based Comp

$982K

No prior period

Revenue & EPS history

Nkgen Biotech · Revenue · Quarterly

$0

Q2 2023

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 17 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

+6.0%

Avg return

Earnings day

-0.7%

Avg return

5 days after

+2.7%

Avg return

30 days after

41%

7 / 17 earnings

Positive

+57.1%

Q1 2024

Best reaction

-16.9%

Q4 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025+0.0%+0.0%+0.0%
Q1 2025+0.0%+0.0%+0.0%
Q2 2025+0.0%+0.0%+85.0%
Q4 2024+21.4%+0.0%-5.0%
Q3 2024+36.1%+4.7%-5.8%
Q2 2024-0.8%-37.1%-64.1%
Q1 2024+57.1%+26.8%+6.3%
Q4 2023-16.9%-10.8%-8.9%
Q3 2023+5.1%+2.6%+37.9%
Q2 2023+0.3%+0.8%-2.9%
Q1 2023+0.3%-0.3%+0.0%
Q4 2022+0.3%-0.3%+0.0%
Q3 2022-0.3%+0.3%+0.5%
Q2 2022+0.0%+0.0%-0.1%
Q1 2022+0.0%+0.3%+0.7%
Q4 2021+0.0%+0.3%+0.7%
Q3 2021+0.0%+0.2%+1.0%
Q1 2021

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro